Literature DB >> 15639799

Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.

Melissa Broe1, Claire E Shepherd, David M A Mann, Elizabeth A Milward, Wei-Ping Gai, Emma Thiel, Glenda M Halliday.   

Abstract

Insoluble alpha-synuclein plays a central role in Lewy body diseases, with considerable controversy as to whether it plays a similar role in Alzheimer's disease (AD). We assessed the tissue location and solubility of cortical alpha-synuclein in AD (without Lewy body formation) compared with controls, using sequential extraction procedures and Western immunoblotting to quantify different alpha-synuclein species in their different solubility states. Controls had no insoluble cortical alpha-synuclein and a ratio of soluble:lipid-associated alpha-synuclein of 1.2-/+0.1. Total alpha-synuclein protein was significantly increased in AD and concentrated within the lipid-associated fraction (soluble:lipid ratio 0.9-/+0.05, soluble:insoluble 1.5-/+0.1, lipid:insoluble 1.7-/+0.1) which proved difficult to localize in paraffin-embedded tissue. Tissues prepared without lipid extraction revealed alpha-synuclein-immunoreactivity in the amorphous components of mature cored AD plaques. This lipid-association of alpha-synuclein in mature AD plaques links this protein with other lipid changes thought to be important in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639799     DOI: 10.1007/BF03033777

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  41 in total

1.  Intraneuronal beta-amyloid immunoreactivity in the CNS.

Authors:  D L Sparks
Journal:  Neurobiol Aging       Date:  1996 Mar-Apr       Impact factor: 4.673

2.  Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation.

Authors:  Y Arai; M Yamazaki; O Mori; H Muramatsu; G Asano; Y Katayama
Journal:  Brain Res       Date:  2001-01-12       Impact factor: 3.252

3.  A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release.

Authors:  M Michikawa; J S Gong; Q W Fan; N Sawamura; K Yanagisawa
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

4.  Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.

Authors:  He-Jin Lee; Chan Choi; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2001-10-25       Impact factor: 5.157

Review 5.  Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.

Authors:  O M El-Agnaf; G B Irvine
Journal:  J Struct Biol       Date:  2000-06       Impact factor: 2.867

6.  Accelerated alpha-synuclein fibrillation in crowded milieu.

Authors:  Vladimir N Uversky; Elisa M Cooper; Kiowa S Bower; Jie Li; Anthony L Fink
Journal:  FEBS Lett       Date:  2002-03-27       Impact factor: 4.124

Review 7.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

8.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Antigen unmasking for immunoelectron microscopy: labeling is improved by treating with sodium ethoxide or sodium metaperiodate, then heating on retrieval medium.

Authors:  J W Stirling; P S Graff
Journal:  J Histochem Cytochem       Date:  1995-02       Impact factor: 2.479

View more
  6 in total

1.  Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro.

Authors:  Nady Braidy; Wei-Ping Gai; Ying Hua Xu; Perminder Sachdev; Gilles J Guillemin; Xing-Mai Jiang; J William O Ballard; Martin P Horan; Zhi Ming Fang; Beng H Chong; Daniel Kam Yin Chan
Journal:  Neurotox Res       Date:  2013-09-12       Impact factor: 3.911

Review 2.  Biochemical, cellular and behavioural aspects of neurodegeneration: the view from down under.

Authors:  David H Small
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 3.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.

Authors:  You-hai Xu; Kui Xu; Ying Sun; Benjamin Liou; Brian Quinn; Rong-hua Li; Ling Xue; Wujuan Zhang; Kenneth D R Setchell; David Witte; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2014-03-05       Impact factor: 6.150

5.  Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.

Authors:  J W Steele; M L Lachenmayer; S Ju; A Stock; J Liken; S H Kim; L M Delgado; I E Alfaro; S Bernales; G Verdile; P Bharadwaj; V Gupta; R Barr; A Friss; G Dolios; R Wang; D Ringe; P Fraser; D Westaway; P H St George-Hyslop; P Szabo; N R Relkin; J D Buxbaum; C G Glabe; A A Protter; R N Martins; M E Ehrlich; G A Petsko; Z Yue; S Gandy
Journal:  Mol Psychiatry       Date:  2012-07-31       Impact factor: 15.992

6.  Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.

Authors:  J W Steele; S Ju; M L Lachenmayer; J Liken; A Stock; S H Kim; L M Delgado; I E Alfaro; S Bernales; G Verdile; P Bharadwaj; V Gupta; R Barr; A Friss; G Dolios; R Wang; D Ringe; A A Protter; R N Martins; M E Ehrlich; Z Yue; G A Petsko; S Gandy
Journal:  Mol Psychiatry       Date:  2012-08-07       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.